FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per respon	se: 0.5								

	Check this box if no longer subject
	to Section 16. Form 4 or Form 5
\cup	obligations may continue. See
	Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Borgeson Blake				2. Issuer Name and Ticker or Trading Symbol RECURSION PHARMACEUTICALS,									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
Doigeson Blake					INC. [RXRX]									X	Direc	tor		10% Ov	vner
(Last)	(Fir	,	Middle	,	3. Date of Earliest Transaction (Month/Day/Year) 05/16/2023										Officer (give title below)			Other (s below)	specify
C/O RECURSION PHARMACEUTICALS											,			2 : ./0		(0)			
41 S. RIO GRANDE STREET				4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable Line)						
(Street)														X Form filed by One Reporting Person					
SALT LAKE LIT 8		4101												Form filed by More than One Reporting Person					
CITY					Rule 10b5-1(c) Transaction Indication														
7.20. 3								_(-	,										
(City) (State) (Zip)											nsaction was r itions of Rule 1					truction or wr	itten pl	lan that is int	ended to
		Table	I - N	Ion-Derivat	tive S	ecur	ities	Ac	quire	d, Di	sposed o	f, or E	3enefic	ially	/ Owr	ned			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye			Executio ear) if any		on Date,				4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4			and 5) Secu		icially d	Forn (D) o	n: Direct or rect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) or (D)	Price		Repor Trans	eported ansaction(s) astr. 3 and 4)			` ,
Class A C	Common Sto	nck		05/16/202	23				S ⁽¹⁾	H	8,885	D	\$5.091	- ` 			D		
Ciass A Common Stock 05/10/202					-						Ψ5.051	72 2712							
		Tab	ole II	l - Derivati، e.g., pu!							oosed of, convertib				Owne	ed			
1. Title of Derivative Security (Instr. 3)	ive Conversion Date Execution Date, Train or Exercise (Month/Day/Year) if any			Transad Code (I	ansaction Number ode (Instr. of		ative rities ired r osed)	Expira (Mont	te Exer ation I th/Day		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	Amount or Number of Shares						

Explanation of Responses:

- $1. \ Sales \ are \ pursuant \ to \ a \ 10b5-1 \ trading \ plan \ adopted \ by \ the \ Reporting \ Person \ on \ September \ 9, \ 2022.$
- 2. The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from \$4.94 to \$5.43 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.

Remarks:

/s/ Jonathan Golightly, attorney-in-fact

05/17/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.